# Curve Biosciences

> Curve Biosciences develops AI-powered blood tests for chronic disease monitoring. Its Whole-Body Atlas contains more than 400,000 manually curated tissue samples used to identify organ-specific DNA methylation signals. Its initial clinical focus is liver disease; the company is advancing validation and commercialization rather than offering a general-purpose consumer health test.

- **Founded:** 2021
- **Headquarters:** Dallas, United States
- **Founders:** Ritish Patnaik (Co-founder and Chief Executive Officer), Shan Wang (Scientific Co-founder and Chief Innovation Officer), Chuba Oyolu (Co-founder and Chief Technology Officer), Nathan Hunkapiller (Co-founder and Chief Scientific Officer), Alice Chen (Co-founder and Chief Operating Officer)
- **Products:** Whole-Body Atlas, Whole-Body Intelligence, Whole-Body Blood Tests, Liver cancer screening program
- **Notable:** Built a tissue atlas exceeding 400,000 samples., Secured a $11.34 million CPRIT grant in November 2024., Announced $40 million Series A financing in October 2025.

## Products & services

- **Whole-Body Atlas** — Reference dataset of more than 400,000 manually curated tissue samples characterized by organ and disease state. Underpins biomarker discovery and model training.
- **Whole-Body Intelligence** — AI platform interpreting organ-specific epigenetic signals in circulating DNA.
- **Whole-Body Blood Tests** — Blood-based chronic disease monitoring tests in development, initially focused on liver cirrhosis and liver inflammation.
- **Liver cancer screening program** — CPRIT-supported clinical utility study of a blood test for high-risk liver disease patients.

## Achievements

- Built a tissue atlas exceeding 400,000 samples.
- Secured a $11.34 million CPRIT grant in November 2024.
- Announced $40 million Series A financing in October 2025.
- Reported a 1,482-patient, 23-site study with 597 patients held out for blinded testing in April 2026.
- Genomic model research accepted as a poster at the LMRL workshop at ICLR 2026.

## Latest updates

- **2026-04** — Appointed hepatologist Amit Singal as Chief Medical Officer on April 2.
- **2026-04** — Announced completed cirrhosis study and genomic AI work accepted at the ICLR LMRL workshop; clinical manuscript preparation was underway.
- **2026-05** — Published CurveChats episode on the liver-first clinical strategy.
- **2026-06** — Published CurveChats episode on multi-organ monitoring and modular laboratory design.
- **2026-06** — Announced a scientific advisory board chaired by Shan Wang, including Imran Haque, Styrmir Sigurjonsson, Peter Washington, Wendy Winckler and James Zou.

## Links

- Website: https://www.curvebio.com/
- LinkedIn: https://www.linkedin.com/company/curvebiosciences/

---

Profile page: https://yespress.io/curve-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-10-03